zurück

Ivacaftor / tezacaftor / elexacaftor (new indication, 50 M € limit exceeded: cystic fibrosis, in combination with ivacaftor, patients aged ≥ 12 years (heterozygous for F508del and gating mutation (including R117H))

Subject:

  • Active Substance: Ivacaftor / tezacaftor / elexacaftor 
  • Name: Kaftrio®
  • Therapeutic area: Cystic fibrosis
  • Pharmaceutical company: Vertex Pharmaceuticals (Germany) GmbH

Time table:

  • Start: 01.06.2021
  • Final decision by G-BA: 19.11. 2021

Final decision:

  • No additional benefit proved